{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:15:53Z","timestamp":1780586153123,"version":"3.54.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s13555-026-01738-6","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T17:35:27Z","timestamp":1778952927000},"page":"3215-3234","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5956-4404","authenticated-orcid":false,"given":"Nada","family":"Elbuluk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0064-8707","authenticated-orcid":false,"given":"April W.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2624-2724","authenticated-orcid":false,"given":"Ronald","family":"Vender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8187-1024","authenticated-orcid":false,"given":"Tina","family":"Bhutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1295-9249","authenticated-orcid":false,"given":"Lawrence","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3000-2165","authenticated-orcid":false,"given":"Laura K.","family":"Ferris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7554-8684","authenticated-orcid":false,"given":"Vivian","family":"Laquer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5788-7445","authenticated-orcid":false,"given":"Angela","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Weisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2927-9735","authenticated-orcid":false,"given":"Wenwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8305-8990","authenticated-orcid":false,"given":"Warren","family":"Winkelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8926-0113","authenticated-orcid":false,"given":"Melinda J.","family":"Gooderham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,16]]},"reference":[{"issue":"4","key":"1738_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-027535","volume":"9","author":"B Strober","year":"2019","unstructured":"Strober B, Greenberg JD, Karki C, et al. Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry. BMJ Open. 2019;9(4):e027535.","journal-title":"BMJ Open"},{"issue":"6","key":"1738_CR2","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2165\/00128071-200506060-00005","volume":"6","author":"AB Kimball","year":"2005","unstructured":"Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6(6):383\u201392.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"1738_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s13555-021-00635-4","volume":"12","author":"M Lebwohl","year":"2022","unstructured":"Lebwohl M, Langley RG, Paul C, et al. Evolution of patient perceptions of psoriatic disease: results from the understanding psoriatic disease leveraging insights for treatment (UPLIFT) survey. Dermatol Ther (Heidelb). 2022;12(1):61\u201378.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"15","key":"1738_CR4","doi-asserted-by":"publisher","first-page":"10473","DOI":"10.1021\/acs.jmedchem.3c00600","volume":"66","author":"S Leit","year":"2023","unstructured":"Leit S, Greenwood J, Carriero S, et al. Discovery of a potent and selective tyrosine kinase 2 inhibitor: TAK-279. J Med Chem. 2023;66(15):10473\u201396.","journal-title":"J Med Chem"},{"key":"1738_CR5","doi-asserted-by":"crossref","unstructured":"Mehrotra S, Sano Y, Halkowycz P, et al. Pharmacological characterization of zasocitinib (TAK-279): an oral, highly selective, and potent allosteric TYK2 inhibitor. J Invest Dermatol. 2025;146(1):214-222.e7.","DOI":"10.1016\/j.jid.2025.05.014"},{"key":"1738_CR6","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.3390\/ijms24043391","volume":"24","author":"L Rusi\u00f1ol","year":"2023","unstructured":"Rusi\u00f1ol L, Puig L. TYK2 targeting in immune-mediated inflammatory diseases. Int J Mol Sci. 2023;24(4):3391","journal-title":"Int J Mol Sci"},{"issue":"10","key":"1738_CR7","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1001\/jamadermatol.2024.2701","volume":"160","author":"AW Armstrong","year":"2024","unstructured":"Armstrong AW, Gooderham M, Lynde C, et al. Tyrosine kinase 2 inhibition with zasocitinib (TAK-279) in psoriasis: a randomized clinical trial. JAMA Dermatol. 2024;160(10):1066\u201374.","journal-title":"JAMA Dermatol"},{"key":"1738_CR8","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1016\/j.ard.2025.05.023","volume":"84","author":"A Kivitz","year":"2025","unstructured":"Kivitz A, Baraliakos X, Muensterman ET, et al. Highly selective tyrosine kinase 2 inhibition with zasocitinib (TAK-279) improves outcomes in patients with active psoriatic arthritis: a randomised phase 2b study. Ann Rheum Dis. 2025;84(10):1660\u201374.","journal-title":"Ann Rheum Dis"},{"key":"1738_CR9","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S380686","author":"L Shang","year":"2022","unstructured":"Shang L, Cao J, Zhao S, Zhang J, He Y. TYK2 in immune responses and treatment of psoriasis. J Inflamm Res. 2022;15:5373\u201385","journal-title":"J Inflamm Res"},{"issue":"8","key":"1738_CR10","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1001\/jamadermatol.2024.1677","volume":"160","author":"G Hjort","year":"2024","unstructured":"Hjort G, Schwarz CW, Skov L, Loft N. Clinical characteristics associated with response to biologics in the treatment of psoriasis: A meta-analysis. JAMA Dermatol. 2024;160(8):830\u20137.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"1738_CR11","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/dth.12160","volume":"27","author":"J Karczewski","year":"2014","unstructured":"Karczewski J, Poniedzia\u0142ek B, Rzymski P, Adamski Z. Factors affecting response to biologic treatment in psoriasis. Dermatol Ther. 2014;27(6):323\u201330.","journal-title":"Dermatol Ther"},{"issue":"3","key":"1738_CR12","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s13555-024-01123-1","volume":"14","author":"A Egeberg","year":"2024","unstructured":"Egeberg A, Conrad C, Gorecki P, et al. Response types and factors associated with response types to biologic therapies in patients with moderate-to-severe plaque psoriasis from two randomized clinical trials. Dermatol Ther (Heidelb). 2024;14(3):745\u201358.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"6","key":"1738_CR13","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s40257-016-0229-x","volume":"17","author":"AW Armstrong","year":"2016","unstructured":"Armstrong AW, Villanueva Quintero DG, Echeverr\u00eda CM, et al. Body region involvement and quality of life in psoriasis: Analysis of a randomized controlled trial of adalimumab. Am J Clin Dermatol. 2016;17(6):691\u20139.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"1738_CR14","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1080\/09546634.2017.1365114","volume":"29","author":"A Blauvelt","year":"2018","unstructured":"Blauvelt A, Muram TM, See K, et al. Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab. J Dermatolog Treat. 2018;29(3):220\u20139.","journal-title":"J Dermatol Treat"},{"issue":"1","key":"1738_CR15","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/bjd.13139","volume":"172","author":"CE Griffiths","year":"2015","unstructured":"Griffiths CE, Sterry W, Brock F, et al. Pattern of response in patients with moderate-to-severe psoriasis treated with etanercept. Br J Dermatol. 2015;172(1):230\u20138.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1738_CR16","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s13555-023-01075-y","volume":"14","author":"M Gooderham","year":"2024","unstructured":"Gooderham M, Vender R, Crowley J, et al. Speed and cumulative responses according to body regions in patients with moderate-to-severe plaque psoriasis treated with ixekizumab (interleukin-17A antagonist) versus guselkumab (interleukin-23p19 inhibitor). Dermatol Ther (Heidelb). 2024;14(2):441\u201351.","journal-title":"Dermatol Ther"},{"issue":"1","key":"1738_CR17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.5021\/ad.2022.34.1.14","volume":"34","author":"SW Son","year":"2022","unstructured":"Son SW, Yu DY, Kim Y, et al. Differences in clinical responses to ustekinumab treatment among body regions: results from a real-world prospective, observational, and multi-center study in Korea. Ann Dermatol. 2022;34(1):14\u201321.","journal-title":"Ann Dermatol"},{"key":"1738_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llaf215","author":"M Lebwohl","year":"2025","unstructured":"Lebwohl M, Gooderham MJ, Warren RB, et al. Outcomes of Psoriasis Area and Severity Index (PASI) and PASI components in two phase III trials of deucravacitinib in patients with moderate to severe plaque psoriasis. Clin Exp Dermatol. 2025;50(10):2030\u20136","journal-title":"Clin Exp Dermatol"},{"issue":"8","key":"1738_CR19","doi-asserted-by":"publisher","first-page":"839","DOI":"10.36849\/JDD.6589","volume":"21","author":"C Porter","year":"2022","unstructured":"Porter C, Woods A, Mendelow M, et al. Unmet needs in psoriasis patients. J Drugs Dermatol. 2022;21(8):839\u201344.","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"1738_CR20","doi-asserted-by":"publisher","first-page":"122","DOI":"10.36849\/JDD.6063","volume":"21","author":"M Augustin","year":"2022","unstructured":"Augustin M, Gallo G, See K, et al. Early response is associated with stable long-term response in psoriasis patients receiving ixekizumab or ustekinumab. J Drugs Dermatol. 2022;21(2):122\u20136.","journal-title":"J Drugs Dermatol"},{"issue":"11","key":"1738_CR21","doi-asserted-by":"publisher","first-page":"971","DOI":"10.2340\/00015555-3245","volume":"99","author":"L Puig","year":"2019","unstructured":"Puig L, Dossenbach M, Berggren L, Ljungberg A, Zachariae C. Absolute and relative Psoriasis Area and Severity Indices (PASI) for comparison of the efficacy of ixekizumab to etanercept and placebo in patients with moderate-to-severe plaque psoriasis: an integrated analysis of UNCOVER-2 and UNCOVER-3 outcomes. Acta Derm Venereol. 2019;99(11):971\u20137.","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"1738_CR22","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1111\/jdv.18010","volume":"36","author":"M Gooderham","year":"2022","unstructured":"Gooderham M, Pinter A, Ferris LK, et al. Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2022;36(6):855\u201365.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1738_CR23","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1111\/bjd.18333","volume":"182","author":"SK Mahil","year":"2020","unstructured":"Mahil SK, Wilson N, Dand N, et al. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). Br J Dermatol. 2020;182(5):1158\u201366.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1738_CR24","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1111\/bjd.14888","volume":"176","author":"J Zweegers","year":"2017","unstructured":"Zweegers J, Roosenboom B, van de Kerkhof PC, et al. Frequency and predictors of a high clinical response in patients with psoriasis on biological therapy in daily practice: results from the prospective, multicenter BioCAPTURE cohort. Br J Dermatol. 2017;176(3):786\u201393.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1738_CR25","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/jdv.12817","volume":"29","author":"L Puig","year":"2015","unstructured":"Puig L. PASI90 response: the new standard in therapeutic efficacy for psoriasis. J Eur Acad Dermatol Venereol. 2015;29(4):645\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"1738_CR26","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1007\/s13555-024-01261-6","volume":"14","author":"M Augustin","year":"2024","unstructured":"Augustin M, Gottlieb AB, Lebwohl M, et al. Complete skin clearance is associated with the greatest benefits to health-related quality of life and perceived symptoms for patients with psoriasis. Dermatol Ther (Heidelb). 2024;14(10):2841\u201357.","journal-title":"Dermatol Ther"},{"issue":"3","key":"1738_CR27","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/jdv.12106","volume":"28","author":"PL Mattei","year":"2013","unstructured":"Mattei PL, Corey KC, Kimball AB. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2013;28(3):333\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1738_CR28","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1177\/247553031700200409","volume":"2","author":"JA Walsh","year":"2017","unstructured":"Walsh JA, Tan H, Valdez H, Duffin KC. Comparative assessment of PASI and variations of PGA\u00d7BSA as measures of psoriasis severity. J Psoriasis Psoriatic Arthritis. 2017;2(4):113\u20138.","journal-title":"J Psoriasis Psoriatic Arthritis"},{"issue":"9","key":"1738_CR29","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1016\/j.jid.2018.01.041","volume":"138","author":"JF Merola","year":"2018","unstructured":"Merola JF, Amato DA, See K, et al. Evaluation of sPGA x BSA as an outcome measure and treatment target for clinical practice. J Invest Dermatol. 2018;138(9):1955\u201361.","journal-title":"J Investig Dermatol"},{"issue":"6","key":"1738_CR30","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jaad.2013.07.040","volume":"69","author":"JA Walsh","year":"2013","unstructured":"Walsh JA, McFadden M, Woodcock J, et al. Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort. J Am Acad Dermatol. 2013;69(6):931\u20137.","journal-title":"J Am Acad Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01738-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01738-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01738-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:53:45Z","timestamp":1780584825000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01738-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,16]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1738"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01738-6","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,16]]},"assertion":[{"value":"27 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nada Elbuluk: consultant, advisory board member, and\/or speaker for AbbVie, Allergan, Avita, Beiersdorf, Canfield, Dior, Eli Lilly, Galderma, Incyte, Janssen, Kao USA, Kenvue, La Roche Posay, L\u2019Oreal, McGraw-Hill, Medscape, Pfizer, Sanofi, Takeda, and VisualDx; grant funding from Pfizer and Eli Lilly; royalties from McGraw-Hill; stock options in VisualDx. April W. Armstrong: research investigator, scientific adviser, and\/or speaker for AbbVie, Almirall, Arcutis Biotherapeutics, ASLAN Therapeutics, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Dermira, EPI, Incyte, Janssen, LEO Pharma, Eli Lilly, Mindera, Nimbus, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, Sun Pharma, and UCB. Ronald Vender: grants\/research support and speaker bureau\/honoraria from AbbVie, Alumis, Amgen, Arcutis Biotherapeutics, Bausch Health, Bristol Myers Squibb, Celltrion,\u00a0JAMP Pharma, Janssen, LEO Pharma, Lilly, Meiji, Novartis, Organon, Orka, Sandoz, Sun Pharma, Takeda, and UCB; speaker bureau fees from AbbVie, Actelion, Amgen, Arcutis Biotherapeutics, Bausch Health, Bristol Myers Squibb, Celgene, Cipher, Eli Lilly, Galderma, GSK, Janssen, LEO Pharma, Merck, Novartis, Pfizer, Sun Pharma, and UCB; consulting fees from AbbVie, Actelion, Amgen, Aralez, Arcutis Biotherapeutics, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Cipher, Eli Lilly, Galderma, GSK, Janssen, Kabi-Care, LEO Pharma, Merck, Novartis, Paladin, Pfizer, Sandoz, Sun Pharma, UCB, and Viatris-Mylan. Tina Bhutani: research funding from Amgen, Castle Biosciences, CorEvitas, Novartis, Pfizer, and Regeneron; adviser for AbbVie, Arcutis Biotherapeutics, ASLAN Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Galderma, Incyte, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, Sanofi, Sun Pharma, Takeda, and UCB; speaker for Amgen, Arcutis Biotherapeutics, Galderma, Janssen, Lilly, and LEO Pharma. Lawrence Green: investigator, adviser, and\/or speaker for AbbVie, Alumis, Amgen, Arcutis Biotherapeutics, Bristol Myers Squibb, Dermavant, Eli Lilly, Highlightll Pharmaceutical, Janssen, Ortho Dermatologics, Sun Pharma, Takeda, UCB, and Ventyx Biosciences. Laura K. Ferris: research funding from AbbVie, Acelyrin, Amgen, Arcutis Biotherapeutics, Aristea, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Dermasensor, DermTech, Eli Lilly, Galderma, Incyte, Janssen, LEO Pharma, Moberg, Mobius, Novartis, Regeneron, SkinAnalytics, UCB, and Verrica; consultant and\/or speaker for AbbVie, Amgen, Arcutis Biotherapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Dermavant, DermTech, Janssen, LEO Pharma, Novartis, Pfizer, Regeneron, and Sanofi. Vivian Laquer: research for AbbVie, Acelyrin, Acrotech, Amgen, Argenx, Arcutis Biotherapeutics, ASLAN Therapeutics, Biofrontera, Bristol Myers Squibb, Cara Therapeutics, Dermavant, Eli Lilly, Galderma, Horizon Therapeutics, Incyte, Janssen, LEO Pharma, Novartis, Padagis, Pfizer, Q32 Bio, Rapt, Sun Pharma, UCB, and Ventyx Biosciences. Angela Moore: research funds from AbbVie, Arcutis Biotherapeutics, Bristol Myers Squibb, Dermavant, Eli Lilly, Janssen, Takeda, and UCB. Jamie Weisman: research grants from AbbVie, Alumis, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Dermira, Eli Lilly, Galderma, Merck, Pfizer, Regeneron, Sanofi, and Takeda. Wenwen Zhang and Warren Winkelman: employees and equity holders in Takeda Development Center Americas, Inc. Melinda J. Gooderham: investigator, speaker, and\/or adviser for AbbVie, Akros, Alumis, Amgen, AnaptysBio, Apogee Therapeutics, Arcutis Biotherapeutics, Aristea, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Dermira, Eli Lilly, Galderma, GSK, Incyte, Inmagene, JAMP Pharma, Janssen, Kyowa Kirin, LEO Pharma, MedImmune, Meiji, MoonLake Immunotherapeutics, Nimbus, Novartis, Pfizer, Q32 Bio, Regeneron, Sanofi Genzyme, Sun Pharma, Takeda, Tarsus Pharmaceuticals, UCB, Union Therapeutics, Ventyx Biosciences, and Vyne Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This study was performed in accordance with ethical principles originating from the Declaration of Helsinki, which are consistent with Good Clinical Practice and applicable regulatory requirements. Patients provided written informed consent before starting the study. The clinical study protocol (and amendments), investigator brochure, samples of informed consent forms and other study-related documents were reviewed and approved by institutional review boards or independent ethics committees of all study sites. Consent for publication was not applicable as no identifying information is included in this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}